Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
AstraZeneca
Medtronic
McKesson

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR ULTRAVIST 150


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ultravist 150

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00244140 ↗ Ultravist: Safety and Efficacy in Computed Tomography of Head and Body Completed Bayer Phase 3 2005-10-01 This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
NCT00876083 ↗ PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination Completed Bayer 2008-03-01 The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.
NCT00926562 ↗ A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients Completed Chinese PLA General Hospital Phase 4 2009-02-01 The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).
NCT01206257 ↗ The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) Completed Bayer 2010-08-01 This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity
NCT01255722 ↗ Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed Guerbet Phase 4 2010-11-01 The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability (quality and interpretability of images).
NCT01415414 ↗ Observational Study of Ultravist in Patients Requiring CECT Completed Bayer 2011-09-01 It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.
NCT01448889 ↗ Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy Unknown status Assaf-Harofeh Medical Center N/A 2009-09-01 Acute renal failure induced by radiographic contrast agents is a known complication of coronary angiography.hypoxia plays a major role in the pathogenesis of Contrast induced nephropathy. The aim of the current study is to investigate the effect of normobaric hyperoxygenation therapy on renal functions in patients at high risk for CIN undergoing coronary angiography. The study is aimed to include 180 consecutive patients with estimated GFR base on the MDRD equation of less than 60 mL/min/1.73 m2 that are candidates for elective coronary angiography. Patients with acute renal failure, acute myocardial infarction, noncompensated congestive heart failure, hemodynamic instability, known sensitivity to contrast media and patients who had been exposed to contrast media during the last 3 months will be excluded. Patients with oxygen blood saturation of less than 94% at room air will also be excluded from the study. Study protocol Patients will be randomly assigned to receive either 100% oxygen by mask (treated group) or breath room air (control group) for duration of 4 hours starting at the beginning of the angiographic procedure. All patients will be treated with 0.9% salin and NAC. Coronary angiography will be performed using nonionic, low osmolar iodine (Ultravist®-370) (Schering, Berlin, Germany). All patients will be hospitalized 1 day before and at least 24 hours following angiography. Blood samples for urea, creatinine and cystatin- C will be drawn on admission, 6, 24 and 48 hours after coronary angiography. Urine sample will be taken 24 hours before angiography and 6, 24 and 48 hours post angiography. In those urine samples the ratio between creatinine to Isoprostanes and NO will be evaluated.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ultravist 150

Condition Name

Condition Name for Ultravist 150
Intervention Trials
Diagnostic Imaging 3
Kidney Failure, Chronic 2
Venous Thromboembolism 1
Abdominal CT 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ultravist 150
Intervention Trials
Kidney Failure, Chronic 2
Renal Insufficiency 2
Venous Thromboembolism 1
Thromboembolism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ultravist 150

Trials by Country

Trials by Country for Ultravist 150
Location Trials
China 23
United States 11
Korea, Republic of 3
Colombia 2
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ultravist 150
Location Trials
Illinois 1
Georgia 1
Florida 1
Arizona 1
South Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ultravist 150

Clinical Trial Phase

Clinical Trial Phase for Ultravist 150
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ultravist 150
Clinical Trial Phase Trials
Completed 8
Unknown status 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ultravist 150

Sponsor Name

Sponsor Name for Ultravist 150
Sponsor Trials
Bayer 5
Chinese PLA General Hospital 1
Guerbet 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ultravist 150
Sponsor Trials
Industry 7
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Merck
Baxter
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.